# Tarsus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tarsus-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Irvine, US
- Website: www.tarsusrx.com
- Total disclosed funding: $60M
- Latest round: Series B (Jan 8, 2020)
- Investors on record: 6

## About

Based in California, US, and founded in 2017 and led by CEO Bobak Azamian, Tarsus Pharmaceuticals, Inc. operates as a manufacturing company providing eye care therapeutics to treat patients with Demodex blepharitis. The firm's product is TP-03, a topical ophthalmic. In February 2024, Tarsus Pharmaceuticals, Inc. raised USD 100 million in private placement, selling 2.81 million shares at USD 32 per share on the Nasdaq Global Select Market under the ticker symbol "TARS". Tarsus Pharmaceuticals, Inc. has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of common stock as part of the listing.

Tarsus Pharmaceuticals, Inc. developed a product known as XDEMVY, which is a treatment for Demodex blepharitis, an ocular disease caused by an infestation of Demodex mites. It helps to solve eyelid inflammation, redness, and irritation and for other eye-related conditions, including meibomian gland disease and rosacea, as well as Lyme disease prevention.

## Funding rounds

- Series B, Jan 8, 2020, $60M — Frazier Healthcare Partners, Aperture Venture Partners, Vivo Capital, Visionary Venture Fund, Flying L Partners, Horowitz Group

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Visionary Venture Fund (https://capitalatlas.ai/funds/visionary-venture-fund) — Series B
- Flying L Partners (https://capitalatlas.ai/funds/flying-l-partners) — Series B
- Horowitz Group — Series B